379 related articles for article (PubMed ID: 30485606)
21. [Immune cell therapy using iPS cells].
Yano H; Kaneko S
Rinsho Ketsueki; 2018; 59(2):225-231. PubMed ID: 29515078
[TBL] [Abstract][Full Text] [Related]
22. Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy.
Patel SJ; Yamauchi T; Ito F
Surg Oncol Clin N Am; 2019 Jul; 28(3):489-504. PubMed ID: 31079802
[TBL] [Abstract][Full Text] [Related]
23. [Pluripotent stem cells as a source for T cell research and clinical application].
Ueda T; Kaneko S
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(2):101-8. PubMed ID: 26016637
[TBL] [Abstract][Full Text] [Related]
24. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
25. Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.
Kenderian SS; June CH; Gill S
Methods Mol Biol; 2017; 1633():267-276. PubMed ID: 28735493
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes.
Ikeda H; Shiku H
Cancer Immunol Immunother; 2015 Jul; 64(7):903-9. PubMed ID: 26041411
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
28. [Cancer immunotherapy by utilizing dedritic cells derived from pluripotent stem cells].
Fukushima S; Ihn H; Nishimura Y; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):113-20. PubMed ID: 21720099
[TBL] [Abstract][Full Text] [Related]
29. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
30. CARTs for Solid Tumors: Feasible or Infeasible?
Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
32. T cell engineering as therapy for cancer and HIV: our synthetic future.
June CH; Levine BL
Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1680):20140374. PubMed ID: 26416683
[TBL] [Abstract][Full Text] [Related]
33. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
34. [Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].
Kanie K; Kaneko S
Gan To Kagaku Ryoho; 2023 May; 50(5):571-576. PubMed ID: 37218314
[TBL] [Abstract][Full Text] [Related]
35. Donor-derived CD19 chimeric antigen receptor T cells.
Singh N; Barrett DM
Curr Opin Hematol; 2015 Nov; 22(6):503-8. PubMed ID: 26457962
[TBL] [Abstract][Full Text] [Related]
36. When CAR Meets Stem Cells.
Lee JM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
38. T Cell Genesis: In Vitro Veritas Est?
Brauer PM; Singh J; Xhiku S; Zúñiga-Pflücker JC
Trends Immunol; 2016 Dec; 37(12):889-901. PubMed ID: 27789110
[TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy for cancer: harnessing the T cell response.
Restifo NP; Dudley ME; Rosenberg SA
Nat Rev Immunol; 2012 Mar; 12(4):269-81. PubMed ID: 22437939
[TBL] [Abstract][Full Text] [Related]
40. T lineage differentiation from induced pluripotent stem cells.
Lei F; Haque R; Weiler L; Vrana KE; Song J
Cell Immunol; 2009; 260(1):1-5. PubMed ID: 19811778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
